LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

Strona główna・Stock List・MannKind Corp

MannKind Corp

Open

SectorHealthcare

3.45 0.29

Buy Sell

Overview

Share price change

24h

Current

Min

3.42

Max

3.57

Key metrics
By Trading Economics
Income	-671K -17M
Sales	-22M 90M
P/E Sector Avg	140.5 50.102
EPS	-0.02
Profit margin	-18.431
Employees	591
EBITDA	5.9M 3.4M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+130.88% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	177M 1B
Previous open	3.16
Previous close	3.45

News Sentiment

By Acuity

49%

51%

150 / 344 Ranking in Healthcare

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 cze 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 cze 2026, 23:38 UTC

Acquisitions, Mergers, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 cze 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 cze 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 cze 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 cze 2026, 22:08 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 cze 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 cze 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 cze 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 cze 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 cze 2026, 21:22 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 cze 2026, 20:46 UTC

Acquisitions, Mergers, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 cze 2026, 20:22 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 cze 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 cze 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 cze 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 cze 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 cze 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 cze 2026, 18:54 UTC

Acquisitions, Mergers, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 cze 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 cze 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 cze 2026, 18:00 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 cze 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 cze 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 cze 2026, 17:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

130.88% upside

12 Months Forecast

Average 8.15 USD 130.88%

High 11 USD

Low 4.75 USD

Based on 6 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Sentiment

By Acuity

150 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.